Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05901818
PHASE1

Safety and Efficacy of Autologous iNSC-DAP in the Treatment of Parkinson's Disease

Sponsor: Xuanwu Hospital, Beijing

View on ClinicalTrials.gov

Summary

This is a phase I, interventional, single arm, open-label, clinical study to evaluate the safety and efficacy of the striatal transplantation of autologous induced neural stem cell-derived DA precursor cells in Parkinson's Disease patients.

Official title: Safety and Efficacy of Autologous Induced Neural Stem Cell-derived Dopaminergic Precursor Cells in the Treatment of Parkinson's Disease

Key Details

Gender

All

Age Range

30 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2023-06-13

Completion Date

2026-12-31

Last Updated

2023-06-22

Healthy Volunteers

No

Interventions

DRUG

Autologous induced neural stem cell-derived DA precursor cells

The autologous induced neural stem cell-derived DA precursor cells will be stereotactically implanted into the striatum of PD patients.

Locations (1)

Xuanwu Hospital Capital Medical University

Beijing, Beijing Municipality, China